CA2100314C - Pharmaceutical composition for the treatment of chronic skin ulcers - Google Patents
Pharmaceutical composition for the treatment of chronic skin ulcersInfo
- Publication number
- CA2100314C CA2100314C CA 2100314 CA2100314A CA2100314C CA 2100314 C CA2100314 C CA 2100314C CA 2100314 CA2100314 CA 2100314 CA 2100314 A CA2100314 A CA 2100314A CA 2100314 C CA2100314 C CA 2100314C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- boric acid
- skin ulcers
- chronic skin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical composition for the treatment of chronic skin ulcers comprises as active ingredient a mixture of 4-chloro-3,5-dimethylphenol and boric acid, together with a pharmaceutically acceptable carrier therefor. The composition of the invention is effective for clearing bacterial infection and stimulating cell growth.
Description
21~031~
. ~
The present invention relates to improvements in the field of topical dermatologic therapy. More particularly, the invention is directed to a pharmaceutical composition for topical use in the treatment of chronic skin ulcers.
Persons suffering from diabetes are prone to ulceration of their extremities such as hands and feet, due to the high sugar content of the blood which impairs blood circulation. Skin ulcers are characterized by a loss of epidermis and at least part of the dermis, which generally leads to chronic bacterial infections. These infections seldom respond to systemic antibiotics since the poor circulatory system of a diabetic prevents an adequate supply of blood to the extremities, and thus of the antibiotics. Topical antibiotics, on the other hand, are ineffective in most bacterial skin infections and may cause allergic contact dermatitis. As a result, the infection cannot be controlled and in order to prevent it from spreading to adjacent parts of the body, the diabetic has no other alternative but to undergo amputation of the infected extremity.
It is therefore an object of the present invention to overcome the above drawbacks and to provide a pharmaceutical composition for the treatment of chronic skin ulcers.
In accordance with the present invention, there is thus provided a pharmaceutical composition for treating chronic skin ulcers and comprising, as active ingredient, a mixture of 4-chloro-3,5-dimethylphenol and boric acid, together with a pharmaceutically acceptable carrier therefor.
. ~
The present invention relates to improvements in the field of topical dermatologic therapy. More particularly, the invention is directed to a pharmaceutical composition for topical use in the treatment of chronic skin ulcers.
Persons suffering from diabetes are prone to ulceration of their extremities such as hands and feet, due to the high sugar content of the blood which impairs blood circulation. Skin ulcers are characterized by a loss of epidermis and at least part of the dermis, which generally leads to chronic bacterial infections. These infections seldom respond to systemic antibiotics since the poor circulatory system of a diabetic prevents an adequate supply of blood to the extremities, and thus of the antibiotics. Topical antibiotics, on the other hand, are ineffective in most bacterial skin infections and may cause allergic contact dermatitis. As a result, the infection cannot be controlled and in order to prevent it from spreading to adjacent parts of the body, the diabetic has no other alternative but to undergo amputation of the infected extremity.
It is therefore an object of the present invention to overcome the above drawbacks and to provide a pharmaceutical composition for the treatment of chronic skin ulcers.
In accordance with the present invention, there is thus provided a pharmaceutical composition for treating chronic skin ulcers and comprising, as active ingredient, a mixture of 4-chloro-3,5-dimethylphenol and boric acid, together with a pharmaceutically acceptable carrier therefor.
Applicant has found quite unexpectedly that 4-chloro-3,5-dimethylphenol when used in admixture with boric acid is highly effective for treating chronic skin ulcers. The composition of the invention not only enables the infection to be cleared up, but also promotes skin granulation without the formation of scars.
In a preferred embodiment of the invention, the composition comprises about 1 wt.% of 4-chloro-3,5-dimethylphenol and about 6 wt.% of boric acid, based on the total weight of the composition. Preferably, the pharmaceutically acceptable carrier is water.
4-Chloro-3,5-dimethylphenol is preferably used in the form of a solution which is sold under the trademark DETTOL and contains about 5 wt.% of 4-chloro-3,5-dimethylphenol, about 8 wt.% of pine oil and about 9 wt.% of isopropyl alcohol, the remainder being water.
Approximately 40 parts by volume of such a solution are admixed with about 7 parts by volume of boric acid, and the resulting solution is diluted with approximately 123 parts by volume of water. A preferred composition according to the invention thus comprises about 1 wt.% of 4-chloro-3,5-dimethylphenol, about 6 wt.% of boric acid, about 2 wt.% of pine oil and about 2 wt.% of isopropyl alcohol, the remainder being water.
The pharmaceutical composition of the invention is applied to the wound area of the skin and maintained in contact therewith for a period of approximately 20 minutes, for example, by immersing the infected extremity in a bath containing the treating solution in the case where the skin ulcer is located on one's hand or foot.
After immersion, the wound area with the treating solution -3 `
thereon is covered with a gauze bandage. Such a treatment is repeated every 12 hours until complete healing of the wound is achieved.
It is believed that 4-chloro-3,5-dimethylphenol and boric acid coact synergistically to suppress bacterial activity and stimulate cell growth. The healing process proceeds without the formation of scars.
The following non-limiting example illustrates the invention.
EXAMPLE
A pharmaceutical composition for treating skin ulcers was prepared by mixing the following ingredients:
- DETTOL : 400 ml - Boric acid : 70 ml - Water : 1230 ml The resulting solution was applied to a chronic skin ulcer on a diabetic's foot by immersing the foot in a bath containing the solution, for a period of approximately 20 minutes. After immersion, the wound area with the treating solution thereon was covered with a gauze bandage. This treatment was repeated every 12 hours. Complete healing of the ulcer was observed after approximately six months of treatment.
In a preferred embodiment of the invention, the composition comprises about 1 wt.% of 4-chloro-3,5-dimethylphenol and about 6 wt.% of boric acid, based on the total weight of the composition. Preferably, the pharmaceutically acceptable carrier is water.
4-Chloro-3,5-dimethylphenol is preferably used in the form of a solution which is sold under the trademark DETTOL and contains about 5 wt.% of 4-chloro-3,5-dimethylphenol, about 8 wt.% of pine oil and about 9 wt.% of isopropyl alcohol, the remainder being water.
Approximately 40 parts by volume of such a solution are admixed with about 7 parts by volume of boric acid, and the resulting solution is diluted with approximately 123 parts by volume of water. A preferred composition according to the invention thus comprises about 1 wt.% of 4-chloro-3,5-dimethylphenol, about 6 wt.% of boric acid, about 2 wt.% of pine oil and about 2 wt.% of isopropyl alcohol, the remainder being water.
The pharmaceutical composition of the invention is applied to the wound area of the skin and maintained in contact therewith for a period of approximately 20 minutes, for example, by immersing the infected extremity in a bath containing the treating solution in the case where the skin ulcer is located on one's hand or foot.
After immersion, the wound area with the treating solution -3 `
thereon is covered with a gauze bandage. Such a treatment is repeated every 12 hours until complete healing of the wound is achieved.
It is believed that 4-chloro-3,5-dimethylphenol and boric acid coact synergistically to suppress bacterial activity and stimulate cell growth. The healing process proceeds without the formation of scars.
The following non-limiting example illustrates the invention.
EXAMPLE
A pharmaceutical composition for treating skin ulcers was prepared by mixing the following ingredients:
- DETTOL : 400 ml - Boric acid : 70 ml - Water : 1230 ml The resulting solution was applied to a chronic skin ulcer on a diabetic's foot by immersing the foot in a bath containing the solution, for a period of approximately 20 minutes. After immersion, the wound area with the treating solution thereon was covered with a gauze bandage. This treatment was repeated every 12 hours. Complete healing of the ulcer was observed after approximately six months of treatment.
Claims (7)
1. A pharmaceutical composition for the treatment of chronic skin ulcers, comprising as active ingredient a mixture of 4-chloro-3,5-dimethylphenol and boric acid, together with a pharmaceutically acceptable carrier therefor.
2. A pharmaceutical composition according to claim 1, comprising about 1 wt.% of 4-chloro-3,5-dimethylphenol and about 6 wt.% of boric acid, based on the total weight of the composition.
3. A pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutically acceptable carrier is water.
4. A pharmaceutical composition according to claim 1 or 2, further comprising about 8 wt.% of pine oil and about 9 wt.% of isopropyl alcohol, based on the total weight of the composition.
5. A pharmaceutical composition according to claim 1, comprising about 40 parts by volume of DETTOL
(trademark), about 7 parts by volume of boric acid and about 123 parts by volume of water.
(trademark), about 7 parts by volume of boric acid and about 123 parts by volume of water.
6. Use of 4-chloro-3,5-dimethylphenol in admixture with boric acid for treating chronic skin ulcers.
7. Use of DETTOL (trademark) in admixture with boric acid for treating chronic skin ulcers.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2100314 CA2100314C (en) | 1993-07-12 | 1993-07-12 | Pharmaceutical composition for the treatment of chronic skin ulcers |
GB9413939A GB2280370A (en) | 1993-07-12 | 1994-07-11 | Pharmaceutical composition for the treatment of chronic skin ulcers |
FR9408541A FR2707497A1 (en) | 1993-07-12 | 1994-07-11 | Pharmaceutical composition for the treatment of chronic skin ulcers. |
DE19944424548 DE4424548A1 (en) | 1993-07-12 | 1994-07-12 | Pharmaceutical composition for the treatment of chronic skin ulcers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2100314 CA2100314C (en) | 1993-07-12 | 1993-07-12 | Pharmaceutical composition for the treatment of chronic skin ulcers |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2100314A1 CA2100314A1 (en) | 1995-01-13 |
CA2100314C true CA2100314C (en) | 1996-04-16 |
Family
ID=4151918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2100314 Expired - Fee Related CA2100314C (en) | 1993-07-12 | 1993-07-12 | Pharmaceutical composition for the treatment of chronic skin ulcers |
Country Status (4)
Country | Link |
---|---|
CA (1) | CA2100314C (en) |
DE (1) | DE4424548A1 (en) |
FR (1) | FR2707497A1 (en) |
GB (1) | GB2280370A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222301A1 (en) * | 2010-02-06 | 2010-09-02 | Javid Mihan Jafari | Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection |
-
1993
- 1993-07-12 CA CA 2100314 patent/CA2100314C/en not_active Expired - Fee Related
-
1994
- 1994-07-11 FR FR9408541A patent/FR2707497A1/en not_active Withdrawn
- 1994-07-11 GB GB9413939A patent/GB2280370A/en not_active Withdrawn
- 1994-07-12 DE DE19944424548 patent/DE4424548A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2100314A1 (en) | 1995-01-13 |
GB2280370A (en) | 1995-02-01 |
GB9413939D0 (en) | 1994-08-31 |
DE4424548A1 (en) | 1995-01-19 |
FR2707497A1 (en) | 1995-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0112852B1 (en) | Pharmaceutical gel composition | |
Heggers et al. | Beneficial effect of Aloe on wound healing in an excisional wound model | |
US4424232A (en) | Treatment of herpes simplex | |
US4725609A (en) | Method of promoting healing | |
US20050181028A1 (en) | Topical composition and method for treating occlusive wounds | |
EP0789584A1 (en) | Application of superoxide dismutase in liposomes | |
DE59209658D1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF Wounds, SCARS AND KELOIDS | |
US4735802A (en) | Topical dermatological composition and method of treatment | |
ATE51343T1 (en) | RASHABLE TOPICAL PREPARATION FOR THERAPY OF PSORIASIS. | |
CA2156481A1 (en) | 5-ht2 receptor antagonist compositions useful in treating venous conditions | |
CA2100314C (en) | Pharmaceutical composition for the treatment of chronic skin ulcers | |
WO1998026789A1 (en) | Microclysmic gel for treatment of tissue trauma and burns | |
EP1143966B1 (en) | Preparation for warts | |
EP0699443B1 (en) | Elder-containing skin preparation | |
US5616619A (en) | Topical composition for burn relief and method of use | |
WO2005077402A1 (en) | Honey based gel formulations | |
US3431340A (en) | Medicinal preparation for the treatment of burns and other traumatic wounds | |
AU687840B2 (en) | Topical composition for burn relief and method of use | |
RU2165754C2 (en) | Ointment for treatment of suppurative-inflammatory diseases, burns, articulation inflammatory diseases, trophic ulcers and sluggish wounds, method of its preparing and method of treatment | |
US5576005A (en) | Effectiveness of wart removal by compositions including propolis | |
AU558482B2 (en) | Pharmaceutical gel composition | |
KR100289906B1 (en) | Dermatological composition | |
US20190209639A1 (en) | Ointment for burn | |
US4039686A (en) | Mange cure | |
JPH0692310B2 (en) | Wound healing agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |